The Janus Obesity ETF (NasdaqGM: SLIM) tracks companies focused on fighting and preventing obesity. It has grown 37% YoY and 33% YTD. As obesity continues to evolve into a global epidemic, this ETF is positioned to show increased growth.
SLIM tracks biotechnology, pharmaceutical and healthcare companies that provide medical services to mitigate the growth of obesity in the US and internationally. These companies are servicing an issue that has shown exponential growth over the past few decades; and the number of obese people is expected to increase still with world population on the rise.
“Obesity is a huge epidemic globally. With an increase of 27.5% amongst adults and a staggering 47.1% amongst children and adolescents over the last 30 years, we have a serious problem on our hands,” says Seeking Alpha.
Due to the growing number of individuals affected by obesity, there is a strong market for servicing these people.
“Worldwide, more than 10% of men and some 14% of women are now classified as obese; those numbers are predicted to climb to 18% of men and 21% of women by 2025. As obesity and overweight levels rise, so do the enormous direct and indirect medical expenditures for treatment and prevention which globally are estimated at $2 trillion annually – creating increased pressure to tackle the issue,” reports Janus Henderson.